HS-20117

HS-20117 (PM1080) is a bispecific antibody developed by Hansoh BioMedical R&D. Its targets are EGFR and MET (the sponsor names EGFR x MET). The sponsor states: A fully-human EGFR-MET IgG1-like bispecific antibody. ClinicalTrials.gov describes the intervention as: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06417008 (A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT06417008, plans to enrol 1080 participants with primary completion expected 2026-06-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.